Comparative Study of 250 mg/day Terbinafine and 100 mg/day Itraconazole for the Treatment of Cutaneous Sporotrichosis

Mycopathologia

Volumn 171, Issue 5, 2011, Pages 349-354

  Francesconi, Glaucia ^a   Francesconi do Valle, Antonio Carlos ^a   Passos, Sonia Lambert ^a   de Lima Barros, Mônica Bastos ^a   de Almeida Paes, Rodrigo ^a   Curi, André Luiz Land ^a   Liporage, José ^a   Porto, Cássio Ferreira ^a   Galhardo, Maria Clara Gutierrez ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Itraconazole; Sporotrichosis; Terbinafine; Treatment

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; NAPHTHALENE DERIVATIVE; TERBINAFINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SPOROTHRIX; SPOROTRICHOSIS;

ADULT; AGED; ANTIFUNGAL AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NAPHTHALENES; SPOROTHRIX; SPOROTRICHOSIS; YOUNG ADULT;

SPOROTHRIX SCHENCKII;

EID: 79953318384     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9380-8     Document Type: Article

References (33)

1. Barros MB, Schubach AO, Schubach TM, et al. An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a serie of cases. Epidemiol Infect. 2008; 136(9): 1192-6.
2. Barros MB, Schubach AO, Valle AC, et al. Cat-transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis. 2004; 38: 529-35.
3. Marimon R, Cano J, Gené J, Sutton DA, Kawasaki M, Guarro J. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol. 2007; 45(10): 3198-206.
4. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2007; 45: 1255-65.
5. Rocha MM, Dassin T, Lira R. Sporotrichosis in patient with AIDS: report of a case and review. Rev Iberoam Micol. 2001; 18(3): 133-6.
6. Bustamante B, Campos PE. Sporotrichosis: a forgotten disease in the drug research agenda. Expert Rev Anti Infect Ther. 2004; 2(1): 85-94.
7. Song Y, Zhong SX, Yao L, Cai Q, Zhou JF, Liu YY, Huo SS, Li SS. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2010. Epub ahead of print.
8. Micromedex DrugDex. E MARTINDALE Itraconazole. The Complete Drug Reference http://www. thomsonhc. com/hcs/librarian/ND_PR/Main/SBK/2/PFPUI/BpY1SQ1yTn4wf/ND_PG/PRIH/CS/97A06F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/5B2E6F/ND_B/HCS/PFActionId/hcs. common. RetrieveDocumentCommon/DocId/2679p/ContentSetId/30/SearchTerm/Itraconazole/SearchOption/BeginWithReference. Accessed 12 Dec 2008.
9. Chapman SW, Pappas P, Kauffmann C, Smith EB, Dietze R, Tiraboschi-Foss N, Restrepo A, Bustamante AB, Opper C, Emady-Azar S, Bakshi R. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1, 000 mg day(-1)) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004; 47(1-2): 62-8.
10. Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol. 1999; 141(Suppl 56): 36-40.
11. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol. 1992; 126(Suppl 39): 51-5.
12. Galhardo MC, De Oliveira RM, Valle ACF, et al. Molecular epidemiology and antifungal susceptibility patterns of Sporothrix schenckii isolates from a cat-transmitted epidemic of sporotrichosis in Rio de Janeiro, Brazil. Medical Mycology. 2008; 46(2): 141-51.
13. Kohler LM, Monteiro PC, Hahn RC, Hamdan JS. In vitro susceptibilities of isolates of Sporothrix schenckii to ITC and terbinafine. J Clin Microbiol. 2004; 42(9): 4319-20.
14. Marimon R, Serena C, Gené J, Cano J, Guarro J. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother. 2008; 52(2): 732-4.
15. Tanuma H, Asai T, Abe M. Case report. Lymphatic vessel-type sporotrichosis immunohistochemical evaluation and cytokine expression pattern. Mycoses. 2001; 44: 316-20.
16. Francesconi G, Valle AF, Passos SRL, Reis R, Galhardo MCG. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2009; 23(11): 1273-6.
17. Noguchi H, Hiruma M, Kawada A. Case report. Sporotrichosis successfully treated with itraconazole in Japan. Mycoses. 1999; 42: 571-6.
18. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitis and cutaneous sporotrichosis. Arch Dermatol. 1986; 122: 413-7.
19. Conti-Diaz IA, Civita E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses. 1992; 35: 153-6.
20. Faergemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol. 1991; 71(4): 322-6.
21. Micromedex DrugDex E MARTINDALE Terbinafine. The Complete Drug Reference http://www. thomsonhc. com/hcs/librarian/ND_PR/Main/SBK/2/PFPUI/BpY1SQ1yTn4wf/ND_PG/PRIH/CS/97A06F/ND_T/HCS/ND_P/Main/DUPLICATIONSHIELDSYNC/5B2E6F/ND_B/HCS/PFActionId/hcs. common. RetrieveDocumentCommon/DocId/2679p/ContentSetId/30/SearchTerm/terbinafine/SearchOption/BeginWithReference. Accessed 12 Dec 2008.
22. Conti-Diaz IA. Epidemiology of sporotrichosis in Latin America. Mycopathologia. 1989; 108: 113-6.
23. Coskun B, Saral Y, et al. Sporotrichosis successfully treated with terbinafine and potassium iodide: Case report and review of literature. Mycopathologia. 2004; 158: 53-6.
24. Gupta AK, Lynde CW, Lauzin GJ, et al. Cutaneous adverse effects associated with terbinafine therapy: 10 case reports and a review of the literature. Br J Dermatol. 1998; 138: 529-32.
25. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole. J Am Acad Dermatol. 1998; 38: S37-41.
26. Kusuhara M, Hachisuka H, Sasai Y. Statistical survey of 150 cases with sporotrichosis. Mycopathologia. 1988; 102: 129-33.
27. Kwon-Chung KJ, Benett JE. Sporotrichosis. In: Kwon-Chung KJ, Benett JE, editors. Medical mycology. Philadelphia: Lea and Febiger; 1992. p. 707.
28. Naranjo CA, Sellers EM, Sander P, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-45.
29. Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Infect Dis. 2000; 30: 65-70.
30. Perez A. Terbinafine: a broad new spectrum of indications in several subcutaneous and systemic mycoses and parasitic diseases. Mycoses. 1999; 42: 150-1.
31. Sampaio S, Lacaz C, Almeida F. Clinical aspects on sporotrichosis in São Paulo. Rev Hosp Clin Fac Med São Paulo. 1954; 9: 391-402.
32. Trilles L, Fernandez-Torres B, Lazera MS, Wanke B, Schubach AO, Paes RA, Inza I, Guarro J. In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases. Antimicrob Agents Chemother. 2005; 49(9): 3952-4.
33. Vickers AE, Sinclair JR, Zollinger M, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999; 27(9): 1029-38.